



Associate Professor Gerry Devlin

Clinical Cardiologist and Interventional
Cardiologist

NZ Heart Foundation

Hamilton

Saturday, June 10, 2017

9:00 - 9:15 Secondary Prevention of IHD

The Challenge of Secondary Prevention

Associate Professor Gerry Devlin
University of Auckland
Medical Director Heart Foundation
Clinical Leader Cardiac Network
Cardiologist
Waikato Hospital





Will

55 year old man with STEMI

Artery opened and stented

Home Day 3




Is this Optimal Care for Will ?



Secondary Prevention of CHD

describes all measures used to help people return to an active and satisfying life post heart event, and reduce their risk of further cardiovascular events.”

- ↓ subsequent events
- ↓ hospitalisation
- ↓ mortality



“To prevent a heart attack, take one aspirin every day. Take it out for a run, then take it to the gym, then take it for a bike ride...”




We have come a long way



ACS -3 Day Cath Target:



Midland Region




National ACS Incidence Rates


(per 100,000 per year)

26% Reduction in Admissions since 2006

ACS Annual Events* by Sex (2006-2013)




ACS Age Standardised Rates* by Sex (2006 - 2013)



*standardised to European Standard Population 2013



So whats the problem?



From 2007 – 2009

**1 in 5 patients admitted to hospital with an
ACS died within one year.**



Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

Tomas Jernberg^{1*}, Pål Hasvold², Martin Henriksson², Hans Hjelm³, Marcus Thuresson⁴, and Magnus Janzon^{5,6}

- Retrospective cohort study from Swedish registries from 2006 to 2011 of 108315 patients post MI alive at 1 week
- Primary composite EP of non fatal MI, stroke or CV death at 1 year and from 12-48 months
- 18% composite EP in first year
- 20% composite EP in next 36 months



Living longer with Heart disease


- Angina
- Atrial Fibrillation
- Heart Failure



**Heart Disease is a Chronic
Condition associated with acute
episodes of care**



CVD events during follow-up in PREDICT population 30-74 years, by clinical history



Back to Will

- Ticagrelor
- Atorvastatin
- Bisoprolol
- Cilazapril
- Aspirin
- GTN Spray
- Referred Cardiac Rehab
- Referred Quit Line



Cardiac Rehabilitation: the Bottomline

- There is evidence of the health benefits of CR
- Effective implementation of CR is suboptimal, with overall participation rates <50%
- CR should include health education and psychological counselling
- CR should offer a choice of community based and home based programmes to fit their needs and preferences
- Clinicians should endorse CR for ACS and heart failure admissions



A national survey of cardiac rehabilitation services in New Zealand - 2015

- A large variety in delivery and content of CR in NZ , with poor understanding of the impact on patient wellbeing
- Just over half of the units (n=20, 56%) used key performance indicators to assess programme impact
- In order for programmes to be effective, it is important to have measurable outcomes and audit feedback for the evaluation of services and patient outcomes



How might we improve secondary prevention?

Common themes

- Robust data collection and audit
- Meaningful patient specific outcomes
- One size does not fit all
- Co design CR
- Use of new technologies
- **Integrated primary / secondary care**




Secondary Prevention

Primary and Secondary Care are expected to work together to provide a community and evidence based prevention programme tailored to individual needs and geographic location for patients with ACS




Core Components of Secondary prevention




Core Components of Secondary prevention



Age-standardised rates of 5-drug prescription at discharge post-ACS, by DHB of domicile (n = 6,129)



% NZders with previous CVD hospitalisations dispensed drugs: statins, BP ↓, antiplatelets, by region 2013



Understanding the Evidence-Practice Gap




Are B-blockers needed for all post ACS?


B-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction

Cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project.

Conclusions: Among survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of b-blockers was not associated with a lower risk of death at any time point up to 1 year.



Assessment of LV Function post ACS



**Can we rationalise therapy to
improve compliance?**




Depression and Heart Disease


- Effects approximately 1 in 3 post ACS
- independently associated with increased cardiovascular morbidity and mortality
- screening tests for depressive symptoms should be used to identify patients who may require further assessment and treatment



The Benefits of Combined Low risk Behaviour



Smoking Cessation



Age	35-44	45-54	55-64	65-74	75-84	85+
With a history of CVD and current smoker	31.4% (n=1,095) 344 smokers	24.7% (n=4,888) 1,207	17.4% (n=10,065) 1,751	9.9% (n=12,246) 1,212	4.1% (n=7,546) 309	1.8% (n=2,128) 38

Effective smoking Interventions

Offering help generates
more quit attempts

Intervention versus comparison

- Brief advice from a health professional vs no intervention
 - Proactive telephone support vs reactive telephone support
 - Automated text messaging vs messaging not related to smoking
 - Face-to-face, individual behavioural support vs brief advice or written materials
 - Face-to-face, group-based behavioural support vs brief advice or written materials
-

Adapted from: West R, Raw M, Dowling S, et al. 2013. Interventions to promote tobacco cessation: a review of effectiveness and affordability for use in national guideline development. Unpublished.



Technology



Associate Professor Ralph Maddison
University of Auckland

**Text4Heart: Enhancing
self-management of cardiovascular
disease**

Empowering Patients



Journeys

*Real people sharing their stories to help
and support others*




You are not alone

There are more than 172,000 people living with some form of heart disease in New Zealand. Read and watch some of their stories, learn from others' life experiences, and find tips to help you and your family/whānau on your journey.

www.heartfoundation.org.nz/journeys

A Comprehensive Lifestyle Peer Group–Based Interventionon Cardiovascular Risk Factors The Randomized Controlled Fifty-Fifty Program

- 543 adults (25 to 50) with at least 1 CV risk factor
- Subjects were randomized 1:1 to a peer group–based intervention group or a self-management control group (CG) for 12 months
- Peer group intervention had beneficial effects on cardiovascular risk factors, with significant improvements in the overall score and specifically on tobacco cessation.



Acute myocardial infarction hospital admissions and deaths in England





Figure 2: Hospital admissions in the 28 days preceding death from acute myocardial infarction
Includes 135 950 deaths with acute myocardial infarction as the underlying cause in people aged 35 years and older.



Heart Attack Awareness



St Johns Chest Pain Responses



Final Thoughts on Improving Secondary Prevention

- Heart Disease is a Chronic condition
- Understand the Evidence- Practice Gap
- Empower Patients
- Primary care role in improving outcomes



“Whilst we must not drop investment in rare conditions and cancer we must redouble efforts and funding on common and chronic conditions”



Rob Califf , Cardiologist
former FDA commissioner

